ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

Geneva, Switzerland — December 11, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies.  In addition, ANAVEX 7-1037 demonstrated its ability to significantly suppress tumor growth in immune-deficient mice.  ANAVEX 7-1037 is the company’s lead drug…